$BMEA

Brookline Capital initiated coverage on Biomea Fusion (BMEA) with a Buy rating and $10 target, citing undervaluation and strong balance sheet. The company is developing icovamenib for diabetes and BMF-650 for obesity. Two Phase 2 trials for icovamenib in type 2 diabetes are ongoing, with topline results expected in Q1 2027. H.C. Wainwright and Citizens also reiterated Buy ratings with $4 and $7 targets, respectively. Biomea canceled a planned public offering due to unfavorable market conditions.

Biomea Fusion Inc. (BMEA) shares fell 10.77% due to negative sentiment around its clinical trial outlook and a terminated equity offering. The company has no revenue, a net loss of $8.3M, and $35.2M in cash. Analysts note high dilution risk and a bearish trend, with resistance at $1.50 and support at $1.20.

Biomea Fusion Inc (BMEA) shares rose 1.2% premarket after canceling a public offering due to unfavorable market conditions. The company, which develops therapies for diabetes and obesity, cited terms unfavorable to shareholders for the cancellation. No securities were sold as part of the offering.

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

Biomea Fusion Inc (BMEA) shares dropped 22.9% after hours Tuesday after announcing a public offering of common stock and pre-funded warrants. The offering includes an option for the underwriter to purchase an additional 15% of shares. The company is focused on developing oral small molecule therapies for diabetes and obesity. The offering is subject to market conditions.

Biomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 22, 2026, Biomea Fusion, Inc. (the “Company”) updated the anticipated timing for topline results from the Company’s ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in October 2026. SIGN

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

Biomea Fusion Inc (BMEA) shares rose 27% after completing enrollment in its Phase II diabetes trial COVALENT-211. The trial evaluates icovamenib in type 2 diabetes patients. Topline results are expected in Q1 2027. H.C. Wainwright analyst reiterated a Buy rating and $4.00 price target, citing potential for future Phase 3 trials.

Biomea Fusion (BMEA) stock rose 5.8% pre-market to $1.45 ahead of anticipated 28-day weight-reduction data from its Phase I GLP-131 trial, expected by Q3 2026. Recent positive developments include the first patient dosed in the OPAL study, analyst optimism, and better-than-expected Q2 earnings. The stock remains below its 52-week high of $2.99.

Biomea Fusion, Inc. (BMEA) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for the quarter calls for revenue of $0 and EPS of -$0.22 (USD).